Pizotifen

CAS No. 15574-96-6

Pizotifen( Pizotifen, Pizotyline )

Catalog No. M12215 CAS No. 15574-96-6

Pizotifen(Pizotyline) is a highly selective 5-HT receptor blocking agent, which is a benzocycloheptane based drug.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
50MG 33 In Stock
100MG 47 In Stock
200MG 66 In Stock
500MG 117 In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    Pizotifen
  • Note
    Research use only, not for human use.
  • Brief Description
    Pizotifen(Pizotyline) is a highly selective 5-HT receptor blocking agent, which is a benzocycloheptane based drug.
  • Description
    Pizotifen(Pizotyline) is a highly selective 5-HT receptor blocking agent, which is a benzocycloheptane based drug.(In Vitro):Pizotifen (BC-105) is a potent 5-HT2 receptor antagonist, with a high affinity for 5-HT1C binding site. Pizotifen is an antidepresent 5-HT2A receptor antagonist and has the capacity to inhibit serotonin-enhanced ADP-induced platelet aggregation.(In Vivo):The weights of the fetuses are significantly reduced by all administered doses of Pipethiadene and Pizotifen (BC-105); the weights of the placentas are significantly reduced after 0.6 and 1.2 mg/kg Pipethiadene and only after the middle dose of Pizotifen. The means of the implantations, live, dead fetuses, resorptions and the occurrence of external, skeletal and visceral anomalies do not differ from the control group. The number of chromosome aberrations in the bone marrow cells of treated mice does not differ significantly from the negative control group. The micronucleus test reveals no elevation in the frequency of micronuclei as compared to the control group. After the two higher doses of both Pipethiadene and Pizotifen (BC-105) maleate, the mitotic indices are lower than in the control group.
  • In Vitro
    Pizotifen (BC-105) is a potent 5-HT2 receptor antagonist, with a high affinity for 5-HT1C binding site. Pizotifen is an antidepresent 5-HT2A receptor antagonist and has the capacity to inhibit serotonin-enhanced ADP-induced platelet aggregation.
  • In Vivo
    The weights of the fetuses are significantly reduced by all administered doses of Pipethiadene and Pizotifen (BC-105); the weights of the placentas are significantly reduced after 0.6 and 1.2 mg/kg Pipethiadene and only after the middle dose of Pizotifen. The means of the implantations, live, dead fetuses, resorptions and the occurrence of external, skeletal and visceral anomalies do not differ from the control group. The number of chromosome aberrations in the bone marrow cells of treated mice does not differ significantly from the negative control group. The micronucleus test reveals no elevation in the frequency of micronuclei as compared to the control group. After the two higher doses of both Pipethiadene and Pizotifen (BC-105) maleate, the mitotic indices are lower than in the control group.
  • Synonyms
    Pizotifen, Pizotyline
  • Pathway
    Endocrinology/Hormones
  • Target
    5-HT Receptor
  • Recptor
    5-HT
  • Research Area
    Neurological Disease
  • Indication
    ——

Chemical Information

  • CAS Number
    15574-96-6
  • Formula Weight
    295.44
  • Molecular Formula
    C19H21NS
  • Purity
    >98% (HPLC)
  • Solubility
    Soluble in DMSO
  • SMILES
    CN1CC/C(CC1)=C2C3=CC=CC=C3CCC4=C\2C=CS4
  • Chemical Name
    4-(9,10-Dihydro-4H-benzo[4,5]cyclohepta[1,2-b]thien-4-ylidene)-1-methylpiperidine

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1.Rahman SM, et al. Pak J Pharm Sci. 2010 Oct;23(4):435-4
molnova catalog
related products
  • Ritanserin

    Ritanserin is a highly effective, relatively selective, long-acting antagonist of 5-HT2 receptor (IC50: 0.9 nM), less active on Histamine H1, Dopamine D2, Adrenergic α1, Adrenergic α2 receptors.

  • AC-90179 HCl

    AC-90179 HCl is a selective inverse agonist of 5-HT2A receptor. AC-90179 HCl is an atypical antipsychotic pharmaceutical and has been shown to alleviate hallucinogen-induced vasocontriction.

  • SB1317

    SB1317 is a potent inhibitor of cyclin dependant kinases (CDKs), Janus kinase 2 (JAK2), and Fms-like tyrosine kinase-3 (FLT3).